Minocycline hydrochloride extended release - Promius Pharma

Drug Profile

Minocycline hydrochloride extended release - Promius Pharma

Alternative Names: DFD-29; Minocycline HCl extended release

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator Promius Pharma
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Rosacea

Most Recent Events

  • 14 Feb 2017 Chemical structure information added
  • 03 Jan 2017 Phase-II clinical trials in Rosacea in Germany (PO) (EudraCT2016-003197-41)
  • 26 Oct 2016 Phase-I clinical trials in Rosacea (PO) before October 2016 (Promius Pharma Pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top